




ORIGINAL RESEARCH

Right Ventricle Has Normal Myofilament Function But Shows Perturbations in the Expression of Extracellular Matrix Genes in Patients With Tetralogy of Fallot Undergoing Pulmonary Valve Replacement

Daniel Brayson , PhD; So-Jin Holohan, PhD; Sonya C. Bardswell, PhD; Matthew Arno, PhD; Han Lu, PhD; Hanna K. Jensen, MD, PhD; Phan Kiet Tran, MD; Javier Barallobre-Barreiro, PhD; Manuel Mayr, MD, PhD; Cristobal G. dos Remedios, MD, PhD; Victor T. Tsang, MD; Alessandra Frigiola , MD*
Jonathan C. Kentish , MA, PhD*

BACKGROUND: Patients with repair of tetralogy of Fallot (rToF) who are approaching adulthood often exhibit pulmonary valve regurgitation, leading to right ventricle (RV) dilatation and dysfunction. The regurgitation can be corrected by pulmonary valve replacement (PVR), but the optimal surgical timing remains under debate, mainly because of the poorly understood nature of RV remodeling in patients with rToF. The goal of this study was to probe for pathologic molecular, cellular, and tissue changes in the myocardium of patients with rToF at the time of PVR.

METHODS AND RESULTS: We measured contractile function of permeabilized myocytes, collagen content of tissue samples, and the expression of mRNA and selected proteins in RV tissue samples from patients with rToF undergoing PVR for severe pulmonary valve regurgitation. The data were compared with nondiseased RV tissue from unused donor hearts. Contractile performance and passive stiffness of the myofilaments in permeabilized myocytes were similar in rToF-PVR and RV donor samples, as was collagen content and cross-linking. The patients with rToF undergoing PVR had enhanced mRNA expression of genes associated with connective tissue diseases and tissue remodeling, including the small leucine-rich proteoglycans ASPN (asporin), LUM (lumican), and OGN (osteo glycin), although their protein levels were not significantly increased.

CONCLUSIONS: RV myofilaments from patients with rToF undergoing PVR showed no functional impairment, but the changes in extracellular matrix gene expression may indicate the early stages of remodeling. Our study found no evidence of major damage at the cellular and tissue levels in the RV of patients with rToF who underwent PVR according to current clinical criteria.

Key Words: extracellular matrix ■ myofibril ■ pulmonary valve replacement ■ small leucine rich proteoglycan ■ tetralogy of Fallot

Tetralogy of Fallot (ToF) is one of the most common congenital heart diseases, accounting for almost 10% of all cardiac malformations.¹ Without surgical intervention, only 10% to 15% of patients survive beyond the age of 20 years. The modern surgical

approach for these patients is for a single-stage repair of ToF (rToF) performed during the first few months of life, which has led to excellent long-term survival (>98% survival at 20 years after repair).² Nevertheless, residual hemodynamic lesions remain and need to

Correspondence to: Jonathan C. Kentish, MA, PhD, School of Cardiovascular Medicine and Sciences and Centre for Human & Applied Physiological Sciences, King's College London, Shepherd's House, Guy's Campus, London SE1 1UL, United Kingdom. E-mail: jon.kentish@kcl.ac.uk and Alessandra Frigiola, MD, MD(res), St Thomas' Hospital, LGF, South Wing, London SE1 7EH, United Kingdom. E-mail: alessandra.frigiola@gstt.nhs.uk

Supplementary Material for this article is available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.119.015342>

*Dr Frigiola and Prof Kentish contributed equally to this work.

For Sources of Funding and Disclosures, see page 18.

© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

JAHA is available at: www.ahajournals.org/journal/jaha

CLINICAL PERSPECTIVE

What Is New?

- We found that contractile function of the myofilaments, taken at the time of pulmonary valve replacement (PVR), in the right ventricular myocardium of patients with repaired tetralogy of Fallot was similar to that of age-matched donor controls.
- Similarly, the extracellular collagen matrix was similar to that in donor control tissue, but there were subtle changes in gene expression, particularly in small leucine-rich proteoglycans, although these changes were not reproduced at the protein level.

What Are the Clinical Implications?

- The optimal timing for PVR in patients with repaired tetralogy of Fallot is controversial.
- It has been suggested that right ventricular dilation over the years preceding PVR could lead to pathologic changes at the tissue and cellular levels that would limit long-term recovery after PVR.
- We found of no evidence of myocyte or extracellular matrix remodeling, which suggests that patients are not exposed to detrimental or irreversible tissue remodeling with current PVR timing guidelines; however, the subtle changes in gene expression may indicate an impending program of myocardial remodeling.

Nonstandard Abbreviations and Acronyms

CMR	cardiac magnetic resonance
ECM	extracellular matrix
EF	ejection fraction
GO	gene ontology
LV	left ventricle
NYHA	New York Heart Association
PVR	pulmonary valve replacement
PCR	polymerase chain reaction
rToF	repair of tetralogy of Fallot
RV	right ventricle
SLRP	small leucine rich proteoglycan

be addressed to avoid long-term detrimental effects. The most common defect is pulmonary regurgitation, which is known to have a deleterious effect on global cardiac function, leading to progressive right ventricle (RV) dilatation and dysfunction, tricuspid valve regurgitation, exercise intolerance, arrhythmias, and sudden death.³⁻⁶ Consequently, pulmonary valve replacement

(PVR) is often advocated for the lifetime management of these patients. PVR has been shown in numerous studies to induce beneficial remodeling, not only of the RV but also the left ventricle (LV),⁷⁻⁹ coupled with improvement in patients' symptoms and exercise capacity.⁷ However, the optimal timing for PVR is controversial. To date, all commercially available pulmonary valves, whether surgically or percutaneously implanted, have limited durability, exposing patients to the need for multiple procedures during their lifetime. Although the number of repeat procedures could be reduced by delaying PVR, any delay could also theoretically lead to irreversible changes in RV structure and function, potentially resulting in poor long-term recovery in some patients after PVR. Therefore, the timing of PVR is critical.

In previous studies, we and others demonstrated post-PVR positive remodeling, characterized by reduction of RV volumes, increase in LV filling, and improvement of biventricular systolic function across a range of ages, but the greatest improvement of LV dynamics and exercise capacity was observed in younger patients (aged <18 years). On preoperative cardiac magnetic resonance (CMR) imaging and echocardiographic assessment, the only difference we observed between younger and older patients was a higher pulmonary valve regurgitant fraction in the younger group, which we interpreted to be the result of a more compliant, less "diseased" RV in younger patients.⁷ However, this suggestion highlighted a major deficiency in knowledge in this field: very little is known about the nature and extent of the pathologic tissue changes that take place in the dilated RV as a result of severe pulmonary valve regurgitation. In other words, by the time PVR is performed, how severe is the cellular and tissue damage in the RV?

Chronic volume overload of the LV (eg, due to myocardial infarction or aortic regurgitation) is associated with changes in the passive stiffness and contractile function of myocytes and in the microarchitecture of the extracellular matrix (ECM) that may either contribute to, or compensate for, mechanical dysfunction.¹⁰⁻¹² However, it is not known if similar pathologies exist in the volume-overloaded RV myocardium of patients with rToF at the time of PVR. In this study, we sought to assess the contractile properties and passive stiffness of the cardiac myofilaments and the composition of the ECM in these patients undergoing PVR to better understand the functional properties at the cellular level of the dilated RV with significant pulmonary regurgitation. In the long term, improved understanding of the nature and extent of maladaptive RV remodeling may help inform therapeutic strategies and aid clinical decisions regarding the time at which PVR should be performed in individual patients with rToF.

METHODS

Data Availability Statement

The data that support the findings of this study are available from the corresponding authors on reasonable request. The microarray data are publicly accessible at the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/geo/>) under accession number GSE141955.

Ethical Approval

The project was approved by the UK National Research Ethics Committee (record 11/LO/1924) and by the local research and development committees of University College London Hospitals, Great Ormond Street Hospital, and Guy's and St Thomas's NHS Foundation Trust. Patients or their legal guardians (as appropriate) were approached at the time of presurgical assessment by one of the research fellows (H.A.J., P.K.T.). Signed informed consent was obtained to allow the excised RV tissue to be retained for experimentation after the removal of residual excessive muscle bundles in the RV outflow tract. Consent was also obtained for the retrospective use of clinical data. To allow comparison with RV samples from nondiseased tissue, we also used frozen samples of RV tissue that had been obtained from 7 unused donor hearts; these were selected so that their sex and age profiles (4 male, 3 female; mean patient age, 28±13 years) resembled those of the patients with rToF undergoing PVR. These samples were obtained from the Sydney Heart Bank, Australia, with full consent of the patients' representatives and with ethics approval (protocol 2012/2814) from the Human Research Ethics Committee of the University of Sydney.

Clinical Assessments

Eight patients (3 male, 5 female; mean patient age, 24±12 years) with previous ToF repair underwent PVR for increasing RV volumes associated with symptoms of shortness of breath on exertion and/or palpitations (median New York Heart Association [NYHA] class II) in agreement with current clinical indications. As part of their clinical preoperative assessment, all patients underwent echocardiogram, CMR, and cardiopulmonary exercise testing, as described below and previously.¹³

Echocardiography

Standard Doppler echocardiography was performed with a VIVID 7 machine (GE Medical Systems) equipped with a multifrequency transducer (3.5 and 5 MHz), as described previously.⁷ From the apical view, tricuspid annular plane systolic excursion was obtained from M-mode interrogation of the lateral aspect

of the tricuspid valve. From the same apical views, tissue Doppler myocardial velocities were obtained at the RV and LV lateral annulus to assess longitudinal function. LV ejection fraction was calculated from the parasternal long-axis view using the Simpson formula. The degree of tricuspid valve regurgitation was assessed qualitatively using color Doppler from the apical 4-chamber view and from the short-axis view; the regurgitation was graded as trivial, mild, moderate, or severe according to the Doppler intensity. From the tricuspid valve regurgitation jet, the RV systolic pressure was obtained using the Bernoulli equation. Peak velocity gradient across the RV outflow tract was calculated from the maximum velocity obtained from the continuous-wave Doppler signal.¹⁴ Pulmonary valve regurgitation was assessed by color and pulsed Doppler interrogation of the pulmonary valve (pressure half time <100 ms) and of the main pulmonary artery and branch pulmonary arteries (presence of reversal flow).

CMR Imaging

CMR was performed with a 1.5-T magnetic resonance scanner (Avanto; Siemens Medical Systems) using techniques described previously.⁷ Assessment of LV and RV volumes was performed by manual segmentation of short-axis cine images at end-diastole and end-systole (Argus; Siemens Medical Systems). End-diastolic and end-systolic volumes were calculated by use of the Simpson rule for each ventricle, and from these volumes, stroke volume and ejection fraction were calculated. Arterial blood flow was calculated from phase contrast images by use of a semiautomatic vessel edge-detection algorithm (Argus; Siemens Medical Systems) with operator correction. Pulmonary valve regurgitant fraction was calculated as percentage of backward flow over forward flow. All volume and flow measurements were indexed for body surface area.

Cardiopulmonary Exercise Testing

Cardiopulmonary exercise testing was performed on an electronically braked bicycle ergometer (ER 900, Ergoline) with respiratory gas exchange analysis. We used a ramp protocol, as described previously.⁷ Peak oxygen uptake, oxygen uptake at the anaerobic threshold, and ventilatory response to carbon dioxide production were derived from respiratory gas analysis during maximal exercise testing; ventilatory response to carbon dioxide production was measured as the slope for the whole exercise.

Functional Studies of Human Permeabilized Cardiac Myocytes

We carried out functional studies of the myofilaments within human single permeabilized cardiac myocytes

that had been prepared from rToF-PVR tissue and RV donor tissue. Myofilament contractile function was assessed from passive myocyte stiffness (at <10 nmol/L Ca^{2+} , which is below the threshold for Ca^{2+} activation of the myofilaments); force production of the myofilaments when maximally activated with Ca^{2+} ($30 \mu\text{mol/L Ca}^{2+}$); maximum rate of force redevelopment after a brief release or restretch of the myocyte during maximal Ca^{2+} activation (which gives information on the rate of actomyosin cross-bridge cycling); and Ca^{2+} sensitivity of myofilament force production, using a range of Ca^{2+} concentrations (0.1 – $30 \mu\text{mol/L}$).

The permeabilized myocytes for these experiments were prepared at 4°C by a modification of the method used previously.¹⁵ A frozen piece of rToF-PVR tissue or donor RV tissue was homogenized for 7 to 10 seconds in a 1-mL ground-glass hand homogenizer containing skinning solution (ie, relaxing solution with 1% Triton X-100; ThermoFisher). Relaxing solution had the following composition (mmol/L): N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (100), K propionate (55), Na_2 phosphocreatine (10), $\text{Na}_2\text{H}_2\text{ATP}$ (6.21; for $\text{MgATP}^{2-}=5$), MgCl_2 (6.24; for $\text{Mg}^{2+}=1$), dithiothreitol (1), EGTA (10; to maintain the free Ca^{2+} concentration at ≈ 1 nmol/L; $-\log_{10}[\text{Ca}^{2+}]$ (pCa) ≈ 9.0), and protease inhibitors leupeptin (0.001), E64 (0.001), and AEBSF (0.25; all from Sigma-Aldrich); pH was 7.1 at 4°C , and ionic strength was 0.20 mol/L. The homogenate in skinning solution was left on ice for 30 minutes for permeabilization of the myocyte membranes, then transferred into a Protein-LoBind Eppendorf tube (Fisher Scientific) and centrifuged ($1500 g$, 4.5 minutes). The myocyte pellet was washed 3 times in relaxing solution (4000 rpm, 4.5 minutes each time) to remove the Triton X-100. The final myocyte suspension in relaxing solution was then stored on ice.

The experimental protocol was modified slightly from that described previously.¹⁵ A permeabilized myocyte was selected, and its ends were glued with UV-setting glue (OA63 adhesive and Opticure LED-200 UV light source; Norland) between pins extending from a force transducer and a high-speed length controller (403A and 315C-I; Aurora Scientific). The mean sarcomere length (SL), measured using an Aurora 600A video analysis system in autocorrelation mode, was set to $2.0 \mu\text{m}$. Myocytes were rejected if the cell was visibly damaged, their end attachments were unstable, the resting sarcomere pattern was unclear or misaligned, the force during Ca^{2+} -activated contraction was unstable, or the resting SL after a contraction was substantially different from that before contraction. These criteria, plus the fact that it was difficult to prepare more than a few myocytes from the small amounts of rToF-PVR tissue available, meant that it was impossible to

obtain useful data from the same number of myocytes from each patient sample. The numbers of data-yielding myocytes from each donor or patient ranged from 1 to 6.

To measure its passive stiffness, the permeabilized myocyte was bathed in relaxing solution at 15°C and given stretches of 1-second duration and various magnitudes to increase SL from $2.0 \mu\text{m}$ to within the range of 2.1 to $2.3 \mu\text{m}$.¹⁵ For this study, we measured the force increment at the end of a stretch from SL 2.0 to $2.3 \mu\text{m}$ and used this increase in resting force as a measure of myocyte passive stiffness.

To examine the Ca^{2+} -activated contractile performance of the permeabilized myocyte, we then perfused the myocyte with a series of CaEGTA-containing activating solutions of Ca^{2+} 0.1 to $30 \mu\text{mol/L}$ (pCa 7.0 – 4.5 ; pH 7.1 ; 15°C).¹⁵ Once force had developed to a steady level (Figure 1A), the myocyte was subjected to a release/restretch protocol to detach all attached myosin crossbridges from actin. The subsequent recovery of force, as crossbridges reattached to actin, was fitted with a single exponential fit, and the rate constant of tension recovery (k_{tr}) was used as a measure of cross-bridge kinetics. Ca^{2+} -activated force was measured as the total steady force in activating solution minus the preceding passive force (at SL $2.0 \mu\text{m}$). The relationship between Ca^{2+} -activated force and Ca^{2+} concentration of the activation solution was fitted with a sigmoidal curve (Hill equation) that was used to calculate the pCa required for 50% activation of force (pCa₅₀).

The sensitivity of these techniques to detect functional changes in myocytes from diseased myocardium was validated in our previous studies, in which we found decreased maximum force but increased k_{tr} and Ca^{2+} sensitivity in myocytes from hypertrophic cardiomyopathy patients¹⁵ and increased Ca^{2+} sensitivity in myocytes from a dilated cardiomyopathy patient.¹⁶

Histologic Quantification of Collagen

Cryosections cut from frozen blocks of tissue were subjected to xylene clearance and sequential ethanol treatment. Slides were left in Milli-Q H_2O for 5 minutes followed by a 30-second incubation in 0.2% phosphomolybdic acid. Slides were rinsed in Milli-Q H_2O and then left in 1% picosirius red solution (to stain for collagen) for 90 minutes. Slides were washed 2×2 minutes in acidified Milli-Q H_2O (0.05% acetic acid), incubated for 15 minutes in picric acid, rinsed 3 times in Milli-Q H_2O , then dehydrated by sequential ethanol treatment (25%, 50%, 75%, 96% [1 minute each]; 100% [2×3 minutes]; xylene [2×5 minutes]). Glass coverslips were mounted with




Figure 1. Passive stiffness and Ca²⁺ activated force in “permeabilized” cardiac myocytes from patients with repair of tetralogy of Fallot undergoing pulmonary valve replacement (rToF-PVR) are similar to those from right ventricle (RV) donors.

A, A typical force trace showing activation of a single myocyte by an increase in solution Ca²⁺ and the measurement of Ca²⁺-activated force and crossbridge kinetics (k_{tr}). For **(B, C, D, and F)**, each small symbol shows the result from 1 myocyte, and each large symbol shows the mean derived from replicate myocytes from each donor or patient. The horizontal bars show the overall mean \pm SD, calculated using each mean value derived from replicate myocytes (large symbols) as a single datum for the statistical analysis. **B**, Passive force, measured as the difference between passive forces at sarcomere lengths 2.0 and 2.3 μm . There were 19 RV donor myocytes (1–6 myocytes from each of 7 donors used in this panel) and 16 rToF-PVR myocytes (1–4 myocytes from each of 6 patients with rToF undergoing PVR used in this panel). **C**, Maximum Ca²⁺-activated force, corrected for myocyte cross-sectional area. There were 23 donor myocytes (1–6 myocytes from each of 7 donors) and 19 rToF-PVR myocytes (1–4 myocytes from each of 7 patients). **D**, Rate of redevelopment of force (k_{tr}) after a release/restretch protocol at maximum Ca²⁺. There were 21 donor myocytes (1–6 myocytes from each of 7 donors) and 19 rToF-PVR myocytes (1–4 myocytes from each of 7 patients). **E**, Force–Ca²⁺ relationship. All forces are expressed relative to the maximum force at 30 $\mu\text{mol/L}$ Ca²⁺. In this panel, the symbols show overall mean \pm SD for each [Ca²⁺]. There were 1 to 6 myocytes from each of 5 donors and 1 to 4 myocytes from each of 7 patients. **F**, Ca²⁺ sensitivity, expressed as the pCa₅₀ value ($-\log_{10}$ of [Ca²⁺] required for 50% activation of force), and serves as a summary variable for the same data as in **(E)**. Statistical analysis showed no significant differences ($P>0.05$, unpaired t tests) between the overall mean data for RV donor and patients with rToF undergoing PVR for any of the measured parameters.

DPX (Sigma-Aldrich) and allowed to dry overnight. Sections were viewed with a light microscope (Zeiss), without and with a polarization filter, to identify collagen organization. Images were captured and analyzed using Volocity software (Perkin Elmer).

Microarray Gene Expression Profiling

RNA extraction was performed on LN₂ cooled and pulverized heart tissue samples using the Direct-zol RNA Miniprep Plus Kit (Zymo Research Corp),

according to the manufacturer's instructions. RNA quality was assessed using the Agilent 2100 bioanalyzer (Agilent Technologies) and quantified using the Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific). All 7 rToF-PVR and 6 of 7 RV donor samples passed quality control and were subsequently subjected to microarray analysis. The gene expression profiles were determined using the GeneChip Human Transcriptome 2.0 Array (Affymetrix; ThermoFisher Scientific). Single-primer isothermal amplified cDNA was generated using the Ovation Pico WTA System V2 Kit (Nugen; AC Leek), following the manufacturer's instructions. In addition, the single-primer isothermal amplified cDNA was subjected to a quality-control check to assess quality (Agilent 2100 bioanalyzer) and quantity (Nanodrop ND-1000 spectrophotometer) in preparation for the next stage. The single-primer isothermal amplified cDNA was fragmented and biotin-labeled using the Encore Biotin Module (Nugen), according to the manufacturer's instructions. The fragmented and biotin-labeled cDNA was subjected to a further round of quality-control checks to assess fragmentation size (Agilent 2100 bioanalyzer). Hybridization cocktails were prepared from the fragmented labeled cDNA according to Nugen's recommendations and hybridized to the microarrays at 45°C for 18 hours. The arrays were washed and stained using the wash protocol FS450_0001 recommended for GeneChip Human Transcriptome 2.0 arrays on the GeneChip Fluidics 450 station. The arrays were scanned using the GeneChip Scanner 3000 7G. CEL files were assessed for quality control in the Expression Console software package (Affymetrix; ThermoFisher Scientific) using standard metrics and guidelines for the Affymetrix microarray system. Principal component analysis, hierarchical clustering, and gene set enrichment analysis were performed in Qlucore Omics Explorer 3.0 (Qlucore, Lund, Sweden). Alignment and comparison to the Gene Ontology (GO) database of biological processes was performed in MetaCore (Thompson Reuters) and used to identify processes and pathways represented by the differentially regulated genes. These microarray data have been submitted to NCBI GEO and are accessible through accession number GSE141955.

Quantitative Polymerase Chain Reaction

Using 2 µg of RNA from the above extraction process, cDNA was synthesized using an RT² First-Strand Kit (Qiagen). Quantitative polymerase chain reaction (PCR) was carried out using the ΔCt method. To start, 9 µL of cDNA was added to 10 µL 2x Sybr Green PCR Master Mix and 5 µmol of forward and reverse primers for the protein of interest (Table 1).

Table 1. Primers Used in This Investigation for Quantitative PCR

Gene	Forward	Reverse
<i>ASPN</i>	5'-CTC TGC CAA ACC CTT CTT TAG C-3'	5'-CGT GAA TAG CAC TGA CAT CCA A-3'
<i>LUM</i>	5'-TAA CTG CCC TGA AAG CTA CCC-3'	5'-GGA GGC ACC ATT GGT ACA CTT-3'
<i>OGN</i>	5'-TCT ACA CTT CTC CTG TTA CTG CT-3'	5'-GAG GTA ATG GTG TTA TTG CCT CA-3'
<i>COL1A2</i>	5'-GAG CGG TAA CAA GGG TGA GC-3'	5'-CAC CCT GTG GTC CAA CAA CTC-3'
<i>COL3A1</i>	5'-GGA GCT GGC TAC TTC TCG C-3'	5'-GGG AAC ATC CTC CTT CAA CAG-3'
<i>LOX</i>	5'-GCC GAC CAA GAT ATT CCT GGG-3'	5'-GCA GGT CAT AGT GGC TAA ACT C-3'
<i>GAPDH</i>	5'-GGA GCG AGA TCC CTC CAA AAT-3'	5'-GGC TGT TGT CAT ACT TCT CAT GG-3'

Cycling parameters were 94°C for 15 seconds, followed by single-step annealing and extension at 60°C for 1 minute (35 cycles). Reactions were carried out in a Corbett RotorGene-3000. The cycle threshold was determined automatically by the software and corresponds to a point during the linear phase of amplification. Gene expression of rToF-PVR samples was expressed as fold change compared with RV donor samples by normalizing individual data points to the mean of RV donors (defined as the control group), which fixed the mean value for the RV donor group to 1.

Extraction of ECM Proteins

Tissue was washed in PBS and then placed in 0.5 mol/L NaCl extraction buffer (1:10 wt/vol) and shaken (at low speed) for 1 hour at room temperature (RT). Decellularization was then performed in 0.1% SDS, with 25 mmol/L EDTA and a 1:100 cocktail of protease inhibitors (1:10 wt/vol) and shaken for 18 hours at RT. Finally, samples were added to 4 mol/L guanidine-HCl (1:5 wt/vol) extraction buffer and shaken vigorously for 48 hours at RT to extract the strongly bound ECM components. Guanidine extracts containing 25 µg of protein were subjected to ethanol precipitation at -20°C overnight after adding 10x the volume of ethanol to the extract lysate. Samples were centrifuged at 14 000g for 45 minutes at 4°C. The supernatants were removed, and the protein-containing pellets were centrifuged in a vacuum centrifuge for 30 minutes at 37°C to dry the pellet completely. The pellets were then subjected to complete deglycosylation to remove any glycosaminoglycan chains or N- and O-linked oligosaccharides that might interfere with antibody binding. Deglycosylation was performed by adding to the pellet a deglycosylation buffer (150 mmol/L NaCl, 50 mmol/L sodium acetate [pH 6.8], 10 mmol/L

EDTA, and supplemented with protease inhibitors) with enzymes: heparinase (1:500), chondroitinase ABC (1:100), keratinase (1:500; all Sigma-Aldrich); PNGaseF (1:200) and 3 different debranching enzymes (α 2-3,6,8,9-neuraminidase [1:200], β -N-acetylglucosaminidase [1:200], and O-glycosidase for complete removal of O-linked sugars (1:200; all from Millipore). These were incubated with shaking for 48 hours at 37°C. Sample buffer containing β -mercaptoethanol was added to the deglycosylated samples to a concentration of 0.5 μ g/ μ L in preparation for western blotting.

Western Blotting

Deglycosylated lysates were heated to 85°C for 10 minutes. A chamber was prepared with a gradient SDS gel of 4% to 16% acrylamide concentration. Next, 5 μ g of 0.5- μ g/ μ L samples were loaded into each well of the gel. The proteins were separated at 175 mV. Transfer was achieved in wet conditions. The proteins were electrophoretically transferred onto nitrocellulose membranes using 350 mA at RT for 2 hours. Membranes were blocked for 1 hour with 5% milk in PBS with Tween. Primary antibodies were added with PBS with Tween/5% BSA and incubated overnight at 4°C. The membrane was washed 3 \times 15 minutes with PBS with Tween. The blots were then incubated in secondary antibody conjugated to horseradish peroxidase for 1 hour. The blots were again washed 3 \times 15 minutes with PBS with Tween, and bound antibody was detected by enhanced chemiluminescence (ECL; GE Healthcare) onto film. Images were scanned and imported to Image Studio Lite (Li-Cor Biosciences) for densitometric analysis.

Immunofluorescence Staining

Tissue was removed from storage at -80°C , warmed to -20°C for ≈ 1 hour, then mounted onto the stage of a cryostat with OCT compound and allowed to equilibrate to the ambient temperature of the cryostat for 5 minutes. For cutting tissue, the stage temperature was set to -22°C , and the knife was set to -20°C . The sections were then cut to 10 μm thick and mounted onto high-quality Superfrost slides (Thermo Fisher Scientific). The sections were allowed to air dry for ≈ 1 hour and then stored at -80°C . For staining, sections were allowed to dry completely and fixed by immersion, in a Coplin jar, in precooled 100% methanol at -20°C for 5 minutes or 4% formalin for 10 minutes at RT. Sections were washed 2 \times 5 minutes in PBS, then permeabilized in 0.5% NP-40 for 3 minutes at RT and washed 3 \times 5 minutes in PBS. Sections were blocked for 1 hour at RT in 5% donkey serum. Primary antibody was diluted appropriately in blocking solution, applied to the sections, and incubated in a humidified chamber

overnight at 4°C. Sections were washed 3 \times 5 minutes in PBS, and secondary antibody conjugated to a fluorophore was diluted as appropriate, applied to the sections, and incubated in the dark in a humidified chamber for 1 hour at RT. DAPI was added 1:10 000 for 5 minutes at the end of the incubation for visualization of nucleic structures. Sections were washed 3 \times 5 minutes in PBS in the dark and then mounted in Mowiol mounting media (Kuraray Specialties Europe GmbH) and allowed to dry in the dark overnight. Images were acquired with an A1R point-scanning confocal microscope (Nikon).

Antibodies

The following antibodies were used in this investigation: anti-asporin (Thermo Fisher [PA5-13553]; polyclonal rabbit IgG, diluted 1:1000 for western blotting and 1:100 for immunofluorescence); anti-lumican (Santa Cruz [sc-33785]; polyclonal rabbit IgG, diluted 1:100 for western blotting); anti-mimican/osteoglycin (Abcam [ab110558]; polyclonal rabbit IgG, diluted 1:1000 for western blotting); anti-myomesin (gift from Elisabeth Ehler; mouse monoclonal IgG, clone B4 diluted 1:100 for immunofluorescence). In the case of asporin, for which band specificity was difficult to determine, we performed sequence alignment of the epitope and discovered homology to biglycan, which has predicted a molecular weight ≈ 5 kDa smaller than asporin; therefore, we believe the lower band visible on the membrane identifies biglycan. We ascribe the higher band to incomplete removal of glycosaminoglycans.

Statistical Analysis

Results of clinical investigations (CMR, cardiopulmonary exercise testing, and echocardiography) were expressed as mean \pm SD. Data from functional experiments, quantitative PCR experiments, and image analysis of picrosirius red staining were plotted individually and expressed as mean \pm SD. As appropriate, the unpaired Student *t* test was applied to test for differences between rToF-PVR and RV donor groups. For the functional data (force, k_{tr} , pCa required for 50% activation of force), the data from multiple myocytes were averaged for each patient and the mean value for each patient was taken as a single datum point for the subsequent calculation of overall mean and SD and *t* tests. Because of the technically challenging nature of the work, the number of myocytes per patient or donor was variable (range, 1–6). If distribution of the data were not normal, the Mann–Whitney test was used, whereas the Welch correction was applied when the variance was unequal between data sets. For transcriptome (mRNA) analysis, 2-group comparison with *t* test was performed, and a threshold *P* value of 0.004 and a false-discovery rate of 0.47 were selected for principal component analysis

and hierarchical clustering. For GO enrichment, a hypergeometric test was used with $P < 0.05$ adjusted by Benjamini-Hochberg correction.

RESULTS

Patient Characteristics

Eight patients underwent PVR, with a mean age of 24 ± 12 years (range, 11–49 years). Seven of 8 patients had a transannular patch at the time of initial rToF and 2 of 8 patients were previously palliated with a right modified Blalock–Taussig shunt. One patient had initial rToF with valve preservation (age, 3 months) and required subsequent balloon valvotomy (age, 9 months) and redo repair with transannular patch (age, 10 months). Only 2 patients had associated comorbidities; 1 patient (age, 15 years at the time of PVR) had mild right hemiplegia as result of an embolic event at the time of primary repair and some hearing impairment, whereas another patient (age, 11 years at the time of PVR) had a history of a high level of consanguinity and presented with intrauterine growth restriction with associated learning difficulties, bilateral Perthes disease, and eczema. Only 1 patient (age, 49 years) was on medication before PVR; medications included β -blocker (bisoprolol 1.25 mg), aspirin 75 mg, and diuretics given only a few weeks before surgery (furosemide 20 mg and spironolactone 25 mg). Patient characteristics are summarized in Table 2. All patients had severe pulmonary valve regurgitation (pulmonary valve regurgitant fraction, $48 \pm 7\%$), whereas there was no evidence of significant residual RV outflow tract obstruction (mean RV outflow tract peak velocity, 2.2 ± 0.4 m/s). The RV was significantly dilated, with an RV end-diastolic volume indexed for body surface area of 149 ± 26 mL/m² and a ratio of 2.2 ± 0.4 for RV:LV end-diastolic volume indexed for body surface area but with preserved systolic function (RV ejection fraction, $56 \pm 5\%$). LV volumes and systolic function were normal in all (mean LV end-diastolic volume indexed for body surface area, 71 ± 19 mL/m²; mean ejection fraction, $66 \pm 7\%$). Two patients had moderate tricuspid valve regurgitation, 1 patient had mild tricuspid valve regurgitation, and the others had trivial or no regurgitation. On cardiopulmonary exercise testing, exercise capacity was found to be reduced only mildly: mean peak oxygen uptake measured 31 ± 8 mL/min per kg ($84 \pm 11\%$ of predicted) with a slope for ventilatory response to carbon dioxide production of 28 ± 4 .

Nondiseased RV tissue samples from 7 unused donor hearts were used as a reference in this study. The donors were selected so that their sex and age profiles (4 male, 3 female; patient age, 28 ± 13 years) resembled

Table 2. Patient Characteristics: Demographic, TTE, CPET, and CMR Imaging Data

	Patients (n=8)
Male:female ratio	3:5
Age at repair, y	2 ± 2.6
Age at PVR, y	24 ± 12
NYHA class, n	
I	2
II	6
TTE	
TAPSE, mm	21 ± 4
TR velocity, m/s	2.5 ± 0.4
RVOT peak velocity, m/s	2.2 ± 0.4
CPET	
Peak $\dot{V}O_2$, mL/min/kg	31 ± 8
Peak $\dot{V}O_2$ % of predicted	84 ± 11
VE/ $\dot{V}CO_2$ slope	28 ± 4
Peak HR, beats/min	180 ± 13
CMR	
RV EDVi, mL/m ²	149 ± 26
RV ESVi, mL/m ²	65 ± 17
RV:LV EDV ratio	$2.2 \pm 0.4:1$
RV CO, L/m ²	6.3 ± 1.8
RV EF, %	56 ± 6
LV EDVi, mL/m ²	71 ± 19
LV EF, %	66 ± 7
LV CO, L/m ²	3.5 ± 0.4
PV RF, %	48 ± 7

CMR indicates cardiac magnetic resonance; CO, cardiac output; CPET, cardiopulmonary exercise testing; EDV, end-diastolic volume; EDVi, end-diastolic volume indexed for body surface area; EF, ejection fraction; ESVi, end-systolic volume indexed for body surface area; HR, heart rate; LV, left ventricle; NYHA, New York Heart Association; PV RF, pulmonary valve regurgitant fraction; PVR, pulmonary valve replacement; RV, right ventricle; TAPSE, tricuspid annular systolic excursion; TR, tricuspid valve regurgitation; TTE, transthoracic echocardiogram; VE/ $\dot{V}CO_2$, ventilatory response to carbon dioxide production; and $\dot{V}O_2$, oxygen uptake.

those of the patients with rToF undergoing PVR. Five of the 7 donors had a subarachnoid hemorrhage after a motor vehicle accident, 1 donor died from a basal infarct after a grand mal seizure, and 1 donor died from hypoxia secondary to a seizure. Before explant, the hearts were classified as “healthy” but were not used for transplantation owing to lack of a tissue-type match. LV or RV tissue from the same hearts has been used as reference tissue in previous publications by our and other laboratories.^{15,17–21}

Stiffness and Contractile Function Were Similar for Permeabilized rToF-PVR and RV Donor Myocytes

Previous studies have found that in left or right heart failure, there are changes in the passive stiffness

and Ca^{2+} -activated force development of the cardiac myofilaments (see Discussion); in vivo, these alterations would be expected to contribute to diastolic and systolic dysfunction, respectively. We investigated whether similar changes could be observed with the myofilaments from the RVs of the patients with rToF undergoing PVR by measuring force development in permeabilized myocytes (Figure 1). The donor and rToF-PVR permeabilized myocytes used in the functional experiments had similar cross-sectional areas: $395 \pm 66 \mu\text{m}^2$ versus $411 \pm 57 \mu\text{m}^2$ for donor and rToF-PVR myocytes, respectively. For each myocyte, we measured the passive stiffness of the myofilaments, as assessed by the increase in passive force on sarcomere stretch from 2.0 to 2.3 μm . There was some variability between the passive stiffnesses of the permeabilized myocytes within and between patient samples, but overall there was no significant difference in passive stiffness between the rToF-PVR and donor myocytes (Figure 1B), with passive forces of $5.36 \pm 1.82 \text{ kN} \cdot \text{m}^{-2}$ ($n=6$ patients) and $4.83 \pm 2.23 \text{ kN} \cdot \text{m}^{-2}$ ($n=7$ donors; $P=0.65$, unpaired t test of patients versus donors), respectively.

Following the passive stiffness measurements, the myocytes were activated with Ca^{2+} , and their Ca^{2+} -activated contractile properties were studied for the following key parameters: maximum Ca^{2+} -activated force (Figure 1C) was $16.3 \pm 5.6 \text{ kN} \cdot \text{m}^{-2}$ in patients with rToF undergoing PVR ($n=7$ patients) and $14.1 \pm 4.1 \text{ kN} \cdot \text{m}^{-2}$ in RV donors ($n=7$ donors; $P=0.42$). Crossbridge cycling kinetics, k_{tr} , at maximal Ca^{2+} (Figure 1D) were $2.01 \pm 0.39 \text{ s}^{-1}$ ($n=7$ patients) and $2.08 \pm 0.23 \text{ s}^{-1}$ ($n=7$ donors; $P=0.70$). The Ca^{2+} sensitivity of force development (Figure 1E), as quantified by the pCa required for 50% activation of force (Figure 1F), was 5.80 ± 0.19 ($n=7$ patients) and 5.80 ± 0.20 ($n=5$ donors; $P=0.97$). Consequently, none of these resting or Ca^{2+} -activated contractile parameters showed a difference between patients with rToF undergoing PVR and donors. From these results, we concluded that the contractile function of myofibrils in permeabilized myocytes from the patients with rToF undergoing PVR was similar to that in donor myocytes.

Collagen Content Was Similar in rToF-PVR and RV Donor Tissue

Collagens I and III are the major ECM protein constituents in the heart and, together with lysyl oxidase, which cross-links the collagen, are known to be the main determinants of tissue stiffness.²² Quantitative PCR for mRNA expression of genes coding for collagen I, collagen III, and lysyl oxidase (*COL1A2*, *COL3A1*, and *LOX*, respectively) revealed that rToF-PVR tissue was comparable with RV donor tissue (Figure 2A). Direct assessment of tissue structure

by picrosirius red showed no quantifiable difference between the collagen content of rToF-PVR and RV donor tissue under either bright-field or circular polarized light (Figure 2B and 2C). The latter was used to visualize only the highly birefringent fibers and to identify potential deleterious organization of collagen that occurs as the fibrotic scar matures. In this setting, only the birefringent (bright) fibers are detected and indicate a predominance of collagen I over collagen III.²³

Transcriptomic Profiling Revealed Upregulation of Small Leucine-Rich Proteoglycans in rToF-PVR

An Affymetrix human microarray was used to profile gene-expression differences between heart tissue of patients with rToF undergoing PVR and RV donors. Principal component analysis, a multivariate analysis that places individual samples in 3-dimensional space relative to each other based on false-discovery rate (q) and P value, was performed. Application of thresholds ($q=0.47$ and $P=0.004$) showed clear clustering of samples within groups and clear separation between rToF-PVR and RV donor samples (Figure 3A) and yielded a list of 601 transcripts, of which 330 encoded known genes (Table S1). Hierarchical clustering showed grouping by disease, with consistent groups of up- and downregulated genes that were evenly distributed (Figure 3B). Volcano analysis showed that the differentially regulated genes carrying the greatest degree of statistical significance were downregulated in rToF-PVR myocardium (Figure 3C). GO pathway analysis clusters the differentially regulated transcripts by utilizing databases of gene names (or "ontologies") based on known associations as found in the existing body of literature. Using this method, we determined that "connective tissue diseases," "response to wounding," "inflammation," and "immune response" were the top scoring terms (ie, ones with the lowest P value) within their categories (diseases by biomarkers, GO processes, process networks, and pathway maps, respectively; Figure 4). Visualization of the top pathway map—immune response_Lectin induced complement pathway—showed that the transcripts in these pathways were predominantly downregulated (Figure 5).

Lists of the 10 most up- and downregulated transcripts according to fold change (Table 3) showed that genes encoding asporin, lumican, and osteoglycin, which are all members of the small leucine-rich proteoglycans (SLRP) family of ECM proteins, were upregulated in rToF-PVR heart tissue compared with RV donor tissue. Gene set enrichment analysis showed that "ECM proteoglycans" displayed a modest




Figure 2. The collagen matrix in myocardium of patients with repair of tetralogy of Fallot undergoing pulmonary valve replacement (rToF-PVR) is similar to that in right ventricle (RV) donor myocardium.

A, quantitative polymerase chain reaction analysis of mRNA expression for COL1A2 (collagen I), COL3A1 (collagen III), and LOX (lysyl oxidase) indicated no differences between rToF-PVR and RV donor myocardium. Each data point shows the result from 1 donor or rToF-PVR patient. **B**, Picrosirius red staining of collagen fibers in RV donor and rToF-PVR heart tissue sections with quantitation of the dark-red-stained collagen fibers as a percentage of total tissue area. **C**, The same sections were viewed under polarized light to assess the presence of irreversibly linked collagen as a percentage of total tissue area. No statistical differences were observed between groups for all assays described. RV donor, n=7; rToF-PVR, n=5. Values are expressed as mean±SD. Scale=30 µm.

enrichment of genes at the leading edges of the analysis, and transcripts were equally distributed between up- and downregulation (Figure 6).

SLRP Gene Expression Is Not Corroborated by Protein Abundance in rToF-PVR Myocardium

To check the transcriptomics data relating to SLRP expression, we used quantitative PCR, which confirmed that genes for asporin (*ASPN*), lumican (*LUM*) and osteoglycin (*OGN*) all underwent significant

increases in mRNA expression in rToF-PVR myocardium (Figure 7A). We then investigated their expression at the protein level. Western blotting showed a band corresponding to the predicted 43-kDa molecular weight for asporin in rToF-PVR samples and showed a trend toward increased expression ($P=0.07$) compared with RV donor samples. Lumican expression was similar between the groups, whereas osteoglycin, which is expressed in preprocessed (~40 kDa) and postprocessed (~20 kDa) forms,²⁴ was expressed heterogeneously within and between groups (Figure 7B). Overall, changes in protein abundance of




Figure 3. Analysis of the transcriptome identifies gene-expression changes in myocardium of patients with repair of tetralogy of Fallot undergoing pulmonary valve replacement (rToF-PVR).

A, Principal component analysis of the gene-expression profile of each tissue sample in relation to all others in the first 3 principal components revealed clear functional grouping of samples according to right ventricle (RV) donor (black) and rToF-PVR (magenta). Each data point shows the result from 1 RV donor or rToF-PVR patient. **B**, Hierarchical clustering also showed rToF-PVR samples were functionally grouped according to gene-expression profile. Selected thresholds were a false-discovery rate (q) of 0.47 and $P=0.004$. **C**, Volcano analysis revealed that the most profound differences occurred in downregulated genes. The transcripts *ASPN*, *LUM*, and *OGN* were upregulated in rToF-PVR samples. Statistical measures applied to the data set before analysis were a P value of 0.004 and a false-discovery rate of 0.47. RV donor, $n=6$; rToF-PVR, $n=7$.

these SLRPs was absent, with the exception perhaps of asporin, which showed a tendency toward an increase in rToF-PVR samples compared with RV donors, though this will need further examination.

Immunofluorescence costaining for asporin and the myofilament protein marker myomesin showed that asporin was mainly localized to nonmyocyte populations but also appeared in the intercalated disc of the myocytes (Figure 8). Subjectively, no obvious differences between cohorts were observed.

DISCUSSION

This investigation is the first, to our knowledge, of myofilament function, tissue structure, and mRNA expression in the RV myocardium of adult, or near-adult, patients with rToF requiring PVR. We found no differences in the passive stiffnesses or the active contractile properties of the myofilaments in rToF-PVR myocytes compared with those in RV myocytes from donor hearts. We discovered subtle molecular differences




Figure 4. Gene ontology (GO) analysis implicated tissue remodeling and inflammation pathways as dysregulated in myocardium of patients with repair of tetralogy of Fallot undergoing pulmonary valve replacement (rToF-PVR).

Holistic analysis of the differentially expressed genes in rToF-PVR myocardium compared with right ventricle donor against the GO-annotated database of affected biological processes ordered according to *P* value.

in the ECM that may indicate an early phase of tissue remodeling in the RV of patients with rToF undergoing PVR; however, the myocardium of patients with rToF undergoing PVR, based on current clinical criteria, appears not to have undergone substantial remodeling at the cellular level, which should be beneficial for successful postoperative recovery.

Functional Assessment of rToF-PVR Cardiomyocytes

Previous studies have established that chronic dilation of the LV, such as that triggered by myocardial infarction or aortic regurgitation, leads to major changes to the contractile apparatus within the




Figure 5. Schematic representation of the top-scoring, statistically significant pathway map indicated downregulation of genes involved in immune response in myocardium of patients with repair of tetralogy of Fallot undergoing pulmonary valve replacement (rToF-PVR).

The top-scoring map (map with the lowest *P* value) based on enrichment distribution sorted by "statistically significant maps" was the Immune response_Lectin induced complement pathway. This shows negative regulation (blue thermometer) of most genes involved in this pathway, implying suppression of immune pathways in rToF-PVR myocardium. Only 1 gene displayed upregulated expression (red thermometer). Many genes in the second and third top-scoring maps overlapped with this map. The material in this figure is reproduced under a licence from Clarivate Analytics. This material may not be copied or redistributed in whole or in part without the written consent of Clarivate Analytics.

Table 3. The 10 Most Upregulated Transcripts and 10 Most Downregulated Protein Coding Transcripts

Gene Name	Gene Symbol	Difference	Fold Change
Upregulated transcripts			
Asporin	<i>ASPN</i>	2.222	4.666
Guanylate cyclase activator 1C	<i>GUCA1C</i>	1.799	3.481
Frizzled-related protein	<i>FRZB</i>	1.383	2.608
Lumican	<i>LUM</i>	1.108	2.156
Natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C)	<i>NPR3</i>	1.027	2.038
Osteoglycin	<i>OGN</i>	0.9933	1.990
Crystallin, mu	<i>CRYM</i>	0.9442	1.924
Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide	<i>FCER1A</i>	0.899	1.865
Fibronectin type III domain containing 1	<i>FNDC1</i>	0.881	1.842
Endothelin receptor type A	<i>EDNRA</i>	0.845	1.797
Downregulated transcripts			
RAS, dexamethasone-induced 1	<i>RASD1</i>	-1.672	0.313
V-set and immunoglobulin domain containing 4	<i>VSIG4</i>	-1.738	0.299
FK506 binding protein 5	<i>FKBP5</i>	-1.770	0.293
S100 calcium binding protein A9	<i>S100A9</i>	-1.800	0.287
Coagulation factor XIII, A1 polypeptide	<i>F13A1</i>	-1.811	0.284
Lymphatic vessel endothelial hyaluronan receptor 1	<i>LYVE1</i>	-1.929	0.262
Phospholipase A2, group IIA (platelets, synovial fluid)	<i>PLA2G2A</i>	-2.035	0.243
Serpin peptidase inhibitor, clade A (alpha-1 antitrypsin, antitrypsin), member 3	<i>SERPINA3</i>	-2.183	0.220
CD163 molecule	<i>CD163</i>	-2.373	0.192
Metallothionein 1A	<i>MT1A</i>	-2.882	0.135

myocytes. For example, the passive stiffness of LV myocytes is increased because of changes in the expression and phosphorylation of the structural protein titin (which links actin and myosin filaments in the myofibril).^{10,12} This would tend to increase the diastolic stiffness of the ventricle. The Ca²⁺ sensitivity of the myofibrils is increased because of reduced phosphorylation of the regulatory protein troponin I,^{10,25} and this would tend to increase systolic contraction of the ventricle while slowing diastolic relaxation. The RV can also show disease-dependent alterations within the myocytes that can influence the contractile state. Permeabilized myocytes from patients with pulmonary arterial hypertension and RV heart failure exhibit increased passive stiffness and maximum Ca²⁺-activated force production compared with donor myocytes, and these changes could contribute to RV diastolic dysfunction in pulmonary arterial hypertension.^{26,27} To our knowledge, there have been no similar studies on the functional properties of myocytes from the volume-overloaded RV tissue of patients with rToF, taken at the time of PVR surgery. We found no difference in passive stiffness of rToF-PVR permeabilized cardiac myocytes compared with myocytes from nondiseased RV tissue (Figure 1). Similarly, the steady-state properties (maximum force production,

Ca²⁺ sensitivity) and dynamic properties (k_{tr}) of the myocytes during Ca²⁺ activation were the same as those from the RV donor controls. Therefore, we did not find any of the pathologic changes in myofibrillar function that have been seen previously in volume-overloaded LV or in pressure-overloaded RV. This result suggests that the rToF-PVR myocytes we studied were structurally sound and that any structural remodeling of the myocytes had not occurred or had not reached a pathologic state detectable by our experiments. In summary, these myocytes were essentially "normal" and did not display a functional phenotype that has been associated with a severely diseased ventricle. Supporting this conclusion, although the RV was severely dilated in these patients, the RV ejection fraction was within the normal range.

Subtle Changes in the ECM of the Remodeled Myocardium in Patients With rToF Undergoing PVR

ECM remodeling in which collagen content is increased is a cardinal feature of heart failure, as studied in LV.²⁸ We observed that collagen content of myocardium was similar between rToF-PVR and RV donor myocardium (Figure 2), which contradicts previous




Figure 6. Gene set enrichment analysis showing the expression patterns of the extracellular matrix (ECM) proteoglycan gene set in patients with repair of tetralogy of Fallot undergoing pulmonary valve replacement (rToF-PVR) compared with right ventricle (RV) donor myocardium.

A. Gene set enrichment analysis of extracellular matrix proteoglycans displaying some enrichment of genes at the leading edge. **B.** Corresponding heat map of genes and expression profiles for 6 RV donor samples and 7 rToF-PVR samples.

studies that showed apparent fibrosis by CMR imaging.²⁹ This finding may reflect the differences in the selectivity of the 2 modes of imaging, as magnetic resonance imaging techniques rely on contrast agents that are thought to target scarred, inflamed, or remodeled areas, whereas picrosirius red staining very specifically detects collagen fibers. We discovered subtle changes in ECM gene expression in rToF-PVR tissue compared with RV donor tissue. Tissue microarray revealed differences in gene expression between donor RV myocardium and rToF PVR myocardium in 601 transcripts when subjected to thresholds of $P < 0.04$ and $q = 0.47$. The selection of these thresholds was determined because samples became functionally grouped at this point. The gene list that was generated (Figure 4) revealed that "connective tissue diseases" were well represented, implicating the ECM changes in diseased tissue. Moreover, 3 of the top 10 transcripts from genes known to encode proteins belonged to the SLRP family. GO analysis of our transcriptomics

data showed that immune-related processes were also strongly implicated, and we hypothesized about whether inflammation contributed to an ECM disease milieu. However, analysis of pathway maps confirmed that the overwhelming majority of the players in the immune pathways were downregulated (Figure 5), making this unlikely. A note of caution is required with regard to the interpretation of our GO analysis because the threshold of $q = 0.47$ is notably low and may have led to substantial false hits. However, this was unavoidable because stricter thresholds would have resulted in a very limited list of genes for GO analysis, and our intention was to validate hits that supported our hypothesis with further experimentation.

Proteoglycans are ECM-modifying proteins that regulate the manner in which the core components of the ECM (ie, collagens) interact with each other and with the surface of cells.³⁰ They are highly negatively charged molecules that can facilitate hydration of the extracellular spaces to form gel-like structures such as




Figure 7. Validation of small leucine-rich proteoglycan (SLRP) gene and protein expression shows asporin to be upregulated in several myocardial samples from patients with tetralogy of Fallot undergoing pulmonary valve replacement (rToF-PVR).

A, The mRNA validation of gene expression was performed by quantitative polymerase chain reaction analysis for the genes encoding asporin (*ASPN*), lumican (*LUM*), and osteoglycin (*OGN*); $n=7$ per group. Each data point shows the result from 1 right ventricle (RV) donor or rToF-PVR patient. Values are expressed as mean±SD, indicated *P* values were returned after performing the Mann–Whitney *U* test. The *P* values were unchanged if the single rToF-PVR outlier was removed and the data were analyzed using the Student unpaired *t* test. **B**, Protein expression analysis for these genes was performed by western blotting using antibodies probing for asporin, lumican, and osteoglycin. Ponceau S shows equal loading of the gel lanes. Densitometry was performed for quantitation of protein abundance relative to ponceau S; RV donor, $n=7$; rToF-PVR, $n=5$.

the glycocalyx on the outer surface of cell membranes, potentially behaving as an ECM lubricant.³¹ The rheologic properties of proteoglycans are important in determining the surface mechanical properties of tissue, and there is a growing realization that dysregulation of proteoglycans may contribute to pathologic remodeling of the myocardium. For example, decorin and biglycan become highly expressed in models of hypertrophy and heart failure and are responsible for facilitating fibrillogenesis and fibrosis.³²

We identified increased mRNA for the SLRP members asporin, lumican, and osteoglycin in rToF-PVR

myocardium. Of these, only asporin displayed a tendency for increased abundance at the protein level in rToF-PVR samples. However, the functional significance of this is unclear at present because little is understood about the role of asporin in the heart. Upregulation of asporin has been observed during ECM remodeling in a pig model of myocardial infarction,³³ but further work is required to establish the importance of asporin in RV function. In conclusion, our study provides evidence that the myocardium of patients with rToF undergoing PVR shows very little disturbance of myofilament function, histologic structure,




Figure 8. Immunostaining of sections for asporin shows localization in extracellular domains and the intercalated disc in human right ventricle.

Asporin expression in right ventricle myocardium of both cohorts appeared in the extracellular domains in between the lateral membranes of cardiomyocytes suggestive of extracellular matrix localization (red arrows) or as regularly spaced bands indicative of intercalated disc staining (white arrows). Antibody to the sarcomere protein, myomesin, was used as a cardiomyocyte marker, and DAPI was used to stain nuclear DNA. Scale bar=10 μ m. PVR indicates pulmonary valve replacement; rToF, repair of tetralogy of Fallot; RV, right ventricle

and protein abundance, whereas gene-expression changes may be indicative of an early response to volume overloading in these patients; however, this requires further investigation.

Clinical Perspectives

Current indications for PVR are based on results of noninvasive assessment, including volumetric and cardiac systolic function assessment with CMR imaging, clinical evaluation of symptoms, and objective assessment of exercise capacity using a cardiopulmonary exercising testing modality. However, it is difficult to predict which patients will most improve after PVR. In a previous study, we found that younger patients (aged <17.5 years) undergoing PVR exhibited greater 1-year improvement of LV dynamics and exercise capacity than older patients. We suggested that the better outcome after PVR in younger patients could be due to a more compliant, less “diseased” RV, perhaps reflecting better myocardial protection at the time of primary repair and shorter exposure to volume

overload.⁷ However, the present results, which were performed mostly on patients in the older age range, did not show evidence of substantial myocardial disease, at least at the cellular and ECM levels. Consequently, in these patients, \approx 20 years after rToF and with severe pulmonary regurgitation, the contractile properties of the RV myofibrils and the ECM composition and structure were comparable to those in normal RV tissue. This suggests that the poorer outcome that we observed previously in the older patient group is unlikely to be caused by poorer reversibility of myocyte and ECM function. Current clinically based predictive indexes used to inform timing of PVR may be fit for purpose and are unlikely to subject patients to the risk of irreversible adverse remodeling of the RV.

We did find subtle changes in the expression of ECM genes in the patients with rToF undergoing PVR. Whether these changes might signal the impending onset of detrimental changes in collagen structure and myofibril function remains a topic for future studies.

Limitations

A main limitation of this study is the small number of available patients and the small amount of tissue that could be obtained from each, which did not allow us to test for any correlation between myocyte or ECM properties and age at the time of PVR. A more extensive study will be needed to address this potential correlation. Another potential limitation comes from the source of the tissue samples in the RV. Of necessity, we could obtain tissue only from the RV infundibulum when removing excessive residual muscle bundles. Although there is the potential that these samples might not be representative of the whole RV myocardium, these tissue sites have been exposed to the same chronic volume overload as the other areas within the RV, so the properties of their myocytes and ECM might be expected to be representative of those throughout the whole RV. Finally, the rToF-PVR samples and the donor samples came from patients with different clinical histories and from 2 different countries (patients undergoing PVR in the United Kingdom; brain-dead patients maintained on life support in Australia). However, using the same donor samples as a reference tissue, many studies have discovered substantial changes in myofilament function in other types of RV or LV disease,²¹ so we have confidence that our finding of no change in myofilament function between the donor and rToF-PVR samples is a valid result.

ARTICLE INFORMATION

Received December 5, 2019; accepted May 28, 2020.

Affiliations

From the School of Cardiovascular Medicine and Sciences (D.B., S.-J.H., S.C.B., J.B.-B., M.M., J.C.K.), Genomics Centre, Faculty of Life Sciences and Medicine King's College London, London, United Kingdom (M.A., H.L.); Great Ormond Street Hospital, London, United Kingdom (H.K.J., P.K.T., V.T.T., A.F.); Department of Anatomy, Bosch Institute University of Sydney, New South Wales, Australia (C.G.d.R.); Guys and St Thomas' NHS Foundation Trust, London, United Kingdom (A.F.); and School of Biomedical Engineering and Imaging Sciences, Kings College, London, United Kingdom (A.F.)

Acknowledgments

All research at Great Ormond Street Hospital NHS Foundation Trust and UCL Great Ormond Street Institute of Child Health is made possible by the National Institute for Health Research (NIHR) Great Ormond Street Hospital Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health. The authors would also like to acknowledge the assistance of the King's College London Genomics Centre in performing the transcriptomics array.

Sources of Funding

This work was supported by British Heart Foundation project grant PG/11/9/28705 (to Kentish, Frigiola, Tsang).

Disclosures

None.

Supplementary Material

Table S1

REFERENCES

- Perry LW, Neill CA, Ferencz C; Eurocat working party on Congenital Heart Disease. *Perspective in Pediatric Cardiology Epidemiology of Congenital Heart Disease, the Baltimore-Washington Infant Study 1981-89*. Armonk, NY: Futura; 1993:33-62.
- Knott-Craig CJ, Elkins RC, Lane MM, Holz J, McCue C, Ward KE. A 26-year experience with surgical management of tetralogy of fallot: Risk analysis for mortality or late reintervention. *Ann Thorac Surg*. 1998;66:506-511.
- Discigil B, Dearani JA, Puga FJ, Schaff HV, Hagler DJ, Warnes CA, Danielson GK. Late pulmonary valve replacement after repair of tetralogy of Fallot. *J Thorac Cardiovasc Surg*. 2001;121:344-351.
- Frigiola A, Redington AN, Cullen S, Vogel M. Pulmonary regurgitation is an important determinant of right ventricular contractile dysfunction in patients with surgically repaired tetralogy of Fallot. *Circulation*. 2004;110:II153-II157.
- Gatzoulis MA, Balaji S, Webber SA, Siu SC, Hokanson JS, Poile C, Rosenthal M, Nakazawa M, Moller JH, Gillette PC, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. *Lancet*. 2000;356:975-981.
- Therrien J, Marx GR, Gatzoulis MA. Late problems in tetralogy of fallot—recognition, management, and prevention. *Cardiol Clin*. 2002;20:395-404.
- Frigiola A, Tsang V, Bull C, Coats L, Khambadkone S, Derrick G, Mist B, Walker F, van Doorn C, Bonhoeffer P, et al. Biventricular response after pulmonary valve replacement for right ventricular outflow tract dysfunction: Is age a predictor of outcome? *Circulation*. 2008;118:S182-S190.
- Heng EL, Gatzoulis MA, Uebing A, Sethia B, Uemura H, Smith GC, Diller GP, McCarthy KP, Ho SY, Li W, et al. Immediate and midterm cardiac remodeling after surgical pulmonary valve replacement in adults with repaired tetralogy of Fallot: a prospective cardiovascular magnetic resonance and clinical study. *Circulation*. 2017;136:1703-1713.
- Oosterhof T, van Straten A, Vliegen HW, Meijboom FJ, van Dijk APJ, Spijkerboer AM, Bouma BJ, Zwinderman AH, Hazekamp MG, de Roos A, et al. Preoperative thresholds for pulmonary valve replacement in patients with corrected tetralogy of Fallot using cardiovascular magnetic resonance. *Circulation*. 2007;116:545-551.
- Hamdani N, Kooij V, van Dijk S, Merkus D, Paulus WJ, Remedios CD, Duncker DJ, Stienen GJ, van der Velden J. Sarcoplasmic dysfunction in heart failure. *Cardiovasc Res*. 2008;77:649-658.
- Hutchinson KR, Stewart JA Jr, Lucchesi PA. Extracellular matrix remodeling during the progression of volume overload-induced heart failure. *J Mol Cell Cardiol*. 2010;48:564-569.
- LeWinter MM, Granzier HL. Titin is a major human disease gene. *Circulation*. 2013;127:938-944.
- Frigiola A, Hughes M, Turner M, Taylor A, Marek J, Giardini A, Hsia TY, Bull K. Physiological and phenotypic characteristics of late survivors of tetralogy of fallot repair who are free from pulmonary valve replacement. *Circulation*. 2013;128:1861-1868.
- Johnson GL, Kwan OL, Handshoe S, Noonan JA, DeMaria AN. Accuracy of combined two-dimensional echocardiography and continuous wave doppler recordings in the estimation of pressure gradient in right ventricular outlet obstruction. *J Am Coll Cardiol*. 1984;3:1013-1018.
- Hoskins A, Jacques AM, Bardswell SC, McKenna WJ, Tsang VT, dos Remedios CG, Ehler E, Avkiran M, Watkins HC, Redwood CS, et al. Normal passive viscoelasticity but abnormal myofibrillar contractile function in patients with obstructive hypertrophic cardiomyopathy. *J Mol Cell Cardiol*. 2010;49:737-745.
- Dyer EC, Jacques AM, Hoskins AC, Ward DG, Gallon CE, Messer AE, Kaski JP, Burch M, Kentish JC, Marston SB. Functional analysis of a unique troponin C mutation, GLY159ASP, that causes familial dilated cardiomyopathy, studied in explanted heart muscle. *Circ Heart Fail*. 2009;2:456-464.
- Gomez-Arroyo J, Mizuno S, Szczepanek K, Van Tassel B, Natarajan R, dos Remedios CG, Drake JI, Farkas L, Kraskauskas D, Wijesinghe DS, et al. Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. *Circ Heart Fail*. 2013;6:136-144.

18. Kruger M, Kotter S, Grutzner A, Lang P, Andresen C, Redfield MM, Butt E, dos Remedios CG, Linke WA. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. *Circ Res*. 2009;104:87–94.
19. Messer AE, Bayliss CR, El-Mezgueldi M, Redwood CS, Ward DG, Leung MC, Papadaki M, Dos Remedios C, Marston SB. Mutations in troponin T associated with hypertrophic cardiomyopathy increase Ca(2+)-sensitivity and suppress the modulation of Ca(2+)-sensitivity by troponin I phosphorylation. *Arch Biochem Biophys*. 2016;601:113–120.
20. Zhang P, Kirk JA, Ji W, dos Remedios CG, Kass DA, Van Eyk JE, Murphy AM. Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human heart. *Circulation*. 2012;126:1828–1837.
21. Dos Remedios CG, Lal SP, Li A, McNamara J, Keogh A, Macdonald PS, Cooke R, Ehler E, Knoll R, Marston SB, et al. The Sydney Heart Bank: Improving translational research while eliminating or reducing the use of animal models of human heart disease. *Biophys Rev*. 2017;9:431–441.
22. Lopez B, Gonzalez A, Hermida N, Valencia F, de Teresa E, Diez J. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. *Am J Physiol Heart Circ Physiol*. 2010;299:H1–H9.
23. Whittaker P, Kloner RA, Boughner DR, Pickering JG. Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. *Basic Res Cardiol*. 1994;89:397–410.
24. Deckx S, Heymans S, Papageorgiou AP. The diverse functions of osteoglycin: a deceitful dwarf, or a master regulator of disease? *FASEB J*. 2016;30:2651–2661.
25. Wolff MR, Buck SH, Stoker SW, Greaser ML, Mentzer RM. Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies: role of altered beta-adrenergically mediated protein phosphorylation. *J Clin Invest*. 1996;98:167–176.
26. Hsu S, Kokkonen-Simon KM, Kirk JA, Kolb TM, Damico RL, Mathai SC, Mukherjee M, Shah AA, Wigley FM, Margulies KB, et al. Right ventricular myofilament functional differences in humans with systemic sclerosis-associated versus idiopathic pulmonary arterial hypertension. *Circulation*. 2018;137:2360–2370.
27. Rain S, Handoko ML, Trip P, Gan CT, Westerhof N, Stienen GJ, Paulus WJ, Ottenheijm CA, Marcus JT, Dorfmueller P, et al. Right ventricular diastolic impairment in patients with pulmonary arterial hypertension. *Circulation*. 2013;128:2016–2025, 2011–2010.
28. Gonzalez A, Lopez B, Ravassa S, San Jose G, Diez J. The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking. *Biochim Biophys Acta Mol Cell Res*. 2019;1866:1421–1432.
29. Yim D, Riesenkampff E, Caro-Dominguez P, Yoo SJ, Seed M, Grosse-Wortmann L. Assessment of diffuse ventricular myocardial fibrosis using native T1 in children with repaired tetralogy of Fallot. *Circ Cardiovasc Imaging*. 2017;10:e005695.
30. Chen S, Birk DE. The regulatory roles of small leucine-rich proteoglycans in extracellular matrix assembly. *FEBS J*. 2013;280:2120–2137.
31. Rabelink TJ, van den Berg BM, Garsen M, Wang G, Elkin M, van der Vlag J. Heparanase: Roles in cell survival, extracellular matrix remodeling and the development of kidney disease. *Nat Rev Nephrol*. 2017;13:201–212.
32. Christensen G, Herum KM, Lunde IG. Sweet, yet underappreciated: proteoglycans and extracellular matrix remodeling in heart disease. *Matrix Biol*. 2019;75–76:286–299.
33. Barallobre-Barreiro J, Didangelos A, Schoendube FA, Drozdov I, Yin X, Fernandez-Caggiano M, Willeit P, Puntmann VO, Aldama-Lopez G, Shah AM, et al. Proteomics analysis of cardiac extracellular matrix remodeling in a porcine model of ischemia/reperfusion injury. *Circulation*. 2012;125:789–802.

Supplemental Material

Table S1. Full List of genes retrieved by applying filtering thresholds of $P=0.004$ and $q=0.47$ to the rToF-PVR vs RV donor microarray.

Gene Symbol	Gene Title	p-value	q-value	Difference	Fold change
ASPN	asporin	0.00095587	0.301	2.222	4.666
GUCA1C	guanylate cyclase activator 1C	0.0007982	0.289	1.800	3.482
FRZB	frizzled-related protein	0.00019086	0.179	1.383	2.609
LUM	lumican	0.00043027	0.223	1.109	2.156
NPR3	natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C)	0.00141221	0.339	1.027	2.038
OGN	osteoglycin	0.00252463	0.400	0.993	1.991
CRYM	crystallin, mu	0.00031254	0.207	0.944	1.924
C8orf4	chromosome 8 open reading frame 4	0.00229581	0.384	0.939	1.918
FCER1A	Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide	0.00164494	0.351	0.900	1.866
FNDC1	fibronectin type III domain containing 1	2.28E-05	0.100	0.882	1.842
KCNJ2-AS1	KCNJ2 antisense RNA 1 (non-protein coding)	0.0004749	0.230	0.859	1.813
EDNRA	endothelin receptor type A	0.00394409	0.468	0.846	1.797
ALS2CR12	amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 12	0.00064006	0.256	0.842	1.792
PDE7B	phosphodiesterase 7B	0.00011862	0.149	0.840	1.790
EPHA7	EPH receptor A7	0.00335361	0.437	0.816	1.761
PLK2	polo-like kinase 2	0.0023682	0.388	0.790	1.729
MN1	meningioma (disrupted in balanced translocation) 1	0.00010048	0.140	0.789	1.728
LOC646168	uncharacterized LOC646168	0.00081887	0.292	0.763	1.697
SOX7	SRY (sex determining region Y)-box 7	0.00325966	0.436	0.713	1.639
NRARP	NOTCH-regulated ankyrin repeat protein	0.00061166	0.251	0.707	1.633
AGTR2	angiotensin II receptor, type 2	0.00216553	0.377	0.702	1.627
ECM2	extracellular matrix protein 2, female organ and adipocyte specific	0.00283864	0.421	0.685	1.608
IFIT2	interferon-induced protein with tetratricopeptide repeats 2	0.0006595	0.259	0.676	1.598
NREP	neuronal regeneration related protein homolog (rat)	0.00253667	0.400	0.661	1.581
LOC100506769	uncharacterized LOC100506769	0.00331014	0.437	0.648	1.567
LOC100270804	uncharacterized LOC100270804	0.00013112	0.156	0.631	1.549
HEG1	HEG homolog 1 (zebrafish)	6.17E-06	0.062	0.615	1.532
CCDC102B	coiled-coil domain containing 102B	0.00134726	0.338	0.586	1.501
TP53INP1	tumor protein p53 inducible nuclear protein 1	0.0033995	0.441	0.574	1.488
C10orf71	chromosome 10 open reading frame 71	0.00359906	0.452	0.557	1.472
PDE5A	phosphodiesterase 5A, cGMP-specific	0.00064754	0.258	0.553	1.468

CNTNAP3	contactin associated protein-like 3	0.00146161	0.340	0.534	1.448
OR10AD1	olfactory receptor, family 10, subfamily AD, member 1	0.00243262	0.394	0.534	1.448
SNORD116-26	small nucleolar RNA, C/D box 116-26	0.00372865	0.460	0.526	1.440
CPE	carboxypeptidase E	0.00021934	0.184	0.520	1.433
SMOC2	SPARC related modular calcium binding 2	0.00019092	0.179	0.513	1.427
HES1	hairy and enhancer of split 1, (Drosophila)	0.00277526	0.419	0.512	1.426
SOX4	SRY (sex determining region Y)-box 4	0.00318828	0.432	0.507	1.421
RN5S320	RNA, 5S ribosomal 320	0.00388418	0.464	0.497	1.411
SERTAD4	SERTA domain containing 4	0.00254978	0.401	0.496	1.410
MIR126	microRNA 126	0.00113114	0.313	0.495	1.409
KCNN3	potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3	3.25E-05	0.115	0.489	1.404
HLTF	helicase-like transcription factor	0.00051927	0.238	0.486	1.401
TTC3P1	tetratricopeptide repeat domain 3 pseudogene 1	0.00231633	0.384	0.478	1.393
TCEAL7	transcription elongation factor A (SII)-like 7	0.00113883	0.313	0.451	1.367
PKD1L1	polycystic kidney disease 1 like 1	0.0003379	0.209	0.450	1.366
PIN4P1	protein (peptidylprolyl cis/trans isomerase) NIMA-interacting, 4 pseudogene 1	0.00035964	0.213	0.447	1.363
HIST1H2AG	histone cluster 1, H2ag /// histone cluster 1, H2ah /// histone cluster 1, H2ai /// histone cluster 1, H2ak /// histone cluster 1, H2al /// histone cluster 1, H2am	0.00090076	0.301	0.439	1.355
ZNF658B	zinc finger protein 658B, pseudogene	0.00111017	0.310	0.430	1.347
CCND1	cyclin D1	0.00051475	0.238	0.417	1.336
FAM129A	family with sequence similarity 129, member A	0.00266643	0.411	0.416	1.334
TET1	tet methylcytosine dioxygenase 1	0.00381215	0.461	0.406	1.325
FAM173B	family with sequence similarity 173, member B	0.00100551	0.303	0.393	1.313
LOC100506123	uncharacterized LOC100506123	0.00133229	0.337	0.390	1.310
ZDHHC15	zinc finger, DHHC-type containing 15	0.00034365	0.209	0.388	1.309
GUSBP2	glucuronidase, beta pseudogene 2 /// glucuronidase, beta pseudogene	0.00393989	0.468	0.386	1.306
ITIH5	inter-alpha-trypsin inhibitor heavy chain family, member 5	2.04E-05	0.096	0.385	1.306
CYSLTR2	cysteinyl leukotriene receptor 2	0.00027762	0.202	0.379	1.301
PTPN21	protein tyrosine phosphatase, non-receptor type 21	0.00097211	0.301	0.369	1.292
LOC100506123	uncharacterized LOC100506123	0.00164761	0.351	0.363	1.286
LRP2BP	LRP2 binding protein	0.00213774	0.375	0.362	1.286
LOC653501	zinc finger protein 658 pseudogene /// zinc finger protein 658 /// zinc finger protein 658B, pseudogene	0.00133441	0.337	0.360	1.283
LOC100653336	uncharacterized LOC100653336	0.00053163	0.242	0.354	1.278
PTCD2	pentatricopeptide repeat domain 2	0.0036253	0.453	0.352	1.276
LOC644135	uncharacterized LOC644135	0.00325367	0.436	0.345	1.270

DDIT3	DNA-damage-inducible transcript 3	0.00111135	0.310	0.341	1.267
CCND2	cyclin D2	0.00160437	0.348	0.332	1.259
	ATPase, H+ transporting, lysosomal accessory protein 1-like /// uncharacterized				
ATP6AP1L	LOC645079	0.00209419	0.370	0.324	1.251
RGS4	regulator of G-protein signaling 4	0.00054283	0.244	0.323	1.251
SYTL2	synaptotagmin-like 2	0.00151955	0.344	0.317	1.246
TRAK1	trafficking protein, kinesin binding 1	0.00092904	0.301	0.313	1.242
C1QTNF7	C1q and tumor necrosis factor related protein 7	0.00227007	0.382	0.306	1.237
ARHGEF9	Cdc42 guanine nucleotide exchange factor (GEF) 9	0.00222169	0.379	0.292	1.224
PAFAH2	platelet-activating factor acetylhydrolase 2, 40kDa	0.00188145	0.367	0.288	1.221
SPTLC3	serine palmitoyltransferase, long chain base subunit 3	0.00247143	0.398	0.283	1.216
STAMBPL1	STAM binding protein-like 1	0.00129268	0.335	0.283	1.216
ZNF624	zinc finger protein 624	0.00206921	0.370	0.280	1.214
PROM1	prominin 1	6.62E-05	0.140	0.273	1.208
DPF3	D4, zinc and double PHD fingers, family 3	0.00247367	0.398	0.271	1.207
LOC100507388	uncharacterized LOC100507388	0.00138663	0.339	0.258	1.196
FAM210A	family with sequence similarity 210, member A	0.00286501	0.421	0.258	1.196
BPHL	biphenyl hydrolase-like (serine hydrolase)	0.00202258	0.370	0.252	1.191
ACOT2	acyl-CoA thioesterase 2	0.00257362	0.402	0.251	1.190
LACE1	lactation elevated 1	0.00149437	0.340	0.249	1.188
PHKA1	phosphorylase kinase, alpha 1 (muscle)	0.00280678	0.420	0.247	1.187
LOC100272216	uncharacterized LOC100272216	0.00297075	0.425	0.247	1.187
CCDC113	coiled-coil domain containing 113	0.00351859	0.446	0.244	1.184
FGD5	FYVE, RhoGEF and PH domain containing 5	0.00351253	0.446	0.241	1.182
PPARGC1A	peroxisome proliferator-activated receptor gamma, coactivator 1 alpha	0.00233201	0.384	0.240	1.181
COPS7B	COP9 constitutive photomorphogenic homolog subunit 7B (Arabidopsis)	0.00062408	0.253	0.240	1.181
ZNF222	zinc finger protein 222	0.00315506	0.432	0.234	1.176
ZNF724P	zinc finger protein 724, pseudogene /// zinc finger protein 724, pseudogene	0.00291976	0.425	0.234	1.176
SNORA38	small nucleolar RNA, H/ACA box 38	0.00148064	0.340	0.225	1.169
MDH1B	malate dehydrogenase 1B, NAD (soluble)	0.00139942	0.339	0.224	1.168
HAPLN1	hyaluronan and proteoglycan link protein 1	0.00270778	0.415	0.224	1.168
LNP1	leukemia NUP98 fusion partner 1	0.00366527	0.455	0.223	1.167
PCSK5	proprotein convertase subtilisin/kexin type 5	0.00120083	0.322	0.219	1.164
ZNF69	zinc finger protein 69	0.00328094	0.437	0.215	1.161
FOXP1	forkhead box P1	0.00251338	0.400	0.208	1.155
RANBP17	RAN binding protein 17	0.00198397	0.370	0.207	1.155

HCG27	HLA complex group 27 (non-protein coding)	0.00273573	0.416	0.201	1.149
MIR1302-8	microRNA 1302-8	0.00296469	0.425	0.195	1.145
PIK3C2B	phosphoinositide-3-kinase, class 2, beta polypeptide	0.00188992	0.367	0.184	1.136
CLEC14A	C-type lectin domain family 14, member A	0.00262711	0.407	0.181	1.133
PCP4	Purkinje cell protein 4	0.00295339	0.425	0.178	1.131
RNASEH2B-AS1	RNASEH2B antisense RNA 1 (non-protein coding)	0.00318168	0.432	0.169	1.124
PHLPP1	PH domain and leucine rich repeat protein phosphatase 1	0.00317698	0.432	0.165	1.121
KIAA1671	KIAA1671	0.00303305	0.426	0.158	1.116
FSIP2	fibrous sheath interacting protein 2	0.00336112	0.437	0.153	1.112
PPIL6	peptidylprolyl isomerase (cyclophilin)-like 6	0.00159178	0.347	0.148	1.108
ZNF440	zinc finger protein 440	0.00382757	0.461	0.142	1.103
MIR4766	microRNA 4766	0.00140201	0.339	0.140	1.102
AGAP2	ArfGAP with GTPase domain, ankyrin repeat and PH domain 2	0.00402441	0.470	0.140	1.102
TNF	tumor necrosis factor	0.00263523	0.408	0.128	1.092
AFF3	AF4/FMR2 family, member 3	0.00225583	0.381	0.127	1.092
OR51Q1	olfactory receptor, family 51, subfamily Q, member 1	0.00317672	0.432	0.124	1.090
FAM66C	family with sequence similarity 66, member C	0.00341159	0.441	0.124	1.090
TAS2R5	taste receptor, type 2, member 5	0.00188549	0.367	0.092	1.066
CCDC94	coiled-coil domain containing 94	0.00330715	0.437	-0.130	0.914
LAIR1	leukocyte-associated immunoglobulin-like receptor 1	0.00393227	0.468	-0.138	0.909
RBM47	RNA binding motif protein 47	0.00265163	0.409	-0.138	0.909
IL18BP	interleukin 18 binding protein	0.00175872	0.355	-0.143	0.906
DOCK2	dedicator of cytokinesis 2	0.00173664	0.355	-0.149	0.902
CMTM7	CKLF-like MARVEL transmembrane domain containing 7	0.0020104	0.370	-0.182	0.882
PCDH1	protocadherin 1	0.00351587	0.446	-0.184	0.880
LOC100288336	Putative uncharacterized protein ENSP00000383251	0.00090383	0.301	-0.186	0.879
EIF2B5-IT1	EIF2B5 intronic transcript 1 (non-protein coding)	0.00231478	0.384	-0.186	0.879
LPIN1	lipin 1	0.00168406	0.352	-0.193	0.875
C16orf57	chromosome 16 open reading frame 57	0.00199218	0.370	-0.199	0.871
PREX1	phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1	0.00148326	0.340	-0.204	0.868
SELPLG	selectin P ligand	0.00134962	0.338	-0.206	0.867
NPL	N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase)	0.00013234	0.156	-0.219	0.859
CHL1-AS2	CHL1 antisense RNA 2 (non-protein coding)	0.00191653	0.368	-0.230	0.853
GRINA	glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding)	0.00252756	0.400	-0.234	0.851
TMEM236	transmembrane protein 236	0.00091526	0.301	-0.236	0.849

SLC4A7	solute carrier family 4, sodium bicarbonate cotransporter, member 7	0.00306824	0.427	-0.237	0.849
TMEM236	transmembrane protein 236	0.00032542	0.207	-0.239	0.848
JMJD6	jumonji domain containing 6	0.00104748	0.308	-0.240	0.847
NT5DC2	5'-nucleotidase domain containing 2	0.00139839	0.339	-0.243	0.845
EMILIN2	elastin microfibril interfacier 2	0.00307184	0.427	-0.246	0.843
MT1IP	metallothionein 1I, pseudogene	0.0020501	0.370	-0.248	0.842
WNK3	WNK lysine deficient protein kinase 3	0.00283373	0.421	-0.249	0.841
SERPINA5	serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5	0.00093116	0.301	-0.249	0.841
NCF4	neutrophil cytosolic factor 4, 40kDa	0.0013664	0.338	-0.252	0.840
TMBIM1	transmembrane BAX inhibitor motif containing 1	0.00105118	0.308	-0.254	0.838
TRHDE	thyrotropin-releasing hormone degrading enzyme	0.00207115	0.370	-0.255	0.838
SLA	Src-like-adaptor	0.00019947	0.179	-0.267	0.831
PRKCD	protein kinase C, delta	0.00306934	0.427	-0.267	0.831
NAGA	N-acetylgalactosaminidase, alpha-	0.00019532	0.179	-0.268	0.831
ALOX5	arachidonate 5-lipoxygenase	0.00325725	0.436	-0.268	0.831
ATG9A	autophagy related 9A	0.00175925	0.355	-0.270	0.829
TMEM204	transmembrane protein 204	0.00115444	0.314	-0.271	0.829
CSTA	cystatin A (stefin A)	2.81E-05	0.104	-0.273	0.828
C1QA	complement component 1, q subcomponent, A chain	0.00345607	0.443	-0.275	0.827
GGT5	gamma-glutamyltransferase 5	0.00147036	0.340	-0.275	0.826
HCK	hemopoietic cell kinase	0.0009889	0.302	-0.276	0.826
WNK1	WNK lysine deficient protein kinase 1	0.00353478	0.447	-0.277	0.825
TMBIM6	transmembrane BAX inhibitor motif containing 6	0.00037047	0.213	-0.280	0.823
SOAT1	sterol O-acyltransferase 1	0.0034374	0.443	-0.285	0.821
NUDT16	nudix (nucleoside diphosphate linked moiety X)-type motif 16	0.00242874	0.394	-0.289	0.818
ADIPOR2	adiponectin receptor 2	0.00400447	0.470	-0.291	0.817
NPC1	Niemann-Pick disease, type C1	0.00173163	0.355	-0.299	0.813
MAP3K6	mitogen-activated protein kinase kinase kinase 6	0.00137857	0.339	-0.300	0.812
STAB1	stabilin 1	0.00159276	0.347	-0.302	0.811
SPTSSA	serine palmitoyltransferase, small subunit A	0.00083432	0.293	-0.314	0.805
H2AFZ	H2A histone family, member Z	0.0005156	0.238	-0.314	0.804
FCN3	ficolin (collagen/fibrinogen domain containing) 3 (Hakata antigen)	0.00225546	0.381	-0.317	0.803
NEDD9	neural precursor cell expressed, developmentally down-regulated 9	0.00097144	0.301	-0.322	0.800
JAK1	Janus kinase 1	0.00335459	0.437	-0.327	0.797
ZNF366	zinc finger protein 366	0.00165299	0.351	-0.327	0.797
SLC1A5	solute carrier family 1 (neutral amino acid transporter), member 5	0.00084604	0.294	-0.335	0.793

CTSB	cathepsin B	0.00180406	0.360	-0.335	0.793
MTCH1	mitochondrial carrier 1	0.0032598	0.436	-0.341	0.790
EFNB1	ephrin-B1	0.0020812	0.370	-0.348	0.786
TOB2	transducer of ERBB2, 2	0.00165455	0.351	-0.355	0.782
IL15RA	interleukin 15 receptor, alpha	0.00054114	0.244	-0.358	0.780
CR1	complement component (3b/4b) receptor 1 (Knops blood group)	0.00020094	0.179	-0.359	0.780
LOC100129027	uncharacterized LOC100129027	0.0004474	0.230	-0.360	0.779
IP6K3	inositol hexakisphosphate kinase 3	0.00090269	0.301	-0.365	0.776
C5orf62	chromosome 5 open reading frame 62	0.00355075	0.447	-0.371	0.773
KLF9	Kruppel-like factor 9	0.00374162	0.460	-0.372	0.773
C1QTNF1	C1q and tumor necrosis factor related protein 1	0.0017507	0.355	-0.373	0.772
EDN1	endothelin 1	0.00293656	0.425	-0.374	0.772
FCGR2B	Fc fragment of IgG, low affinity IIb, receptor (CD32)	0.0018078	0.360	-0.380	0.768
C10orf10	chromosome 10 open reading frame 10	0.00256911	0.402	-0.382	0.768
DDIT4	DNA-damage-inducible transcript 4	0.00060651	0.251	-0.382	0.767
C1RL	complement component 1, r subcomponent-like	0.00221786	0.379	-0.383	0.767
IL18R1	interleukin 18 receptor 1	0.00026271	0.194	-0.392	0.762
CD180	CD180 molecule	0.00208047	0.370	-0.395	0.760
ADORA3	adenosine A3 receptor	0.00286569	0.421	-0.403	0.757
PHF17	PHD finger protein 17	7.48E-05	0.140	-0.404	0.756
LGMN	legumain	0.00201783	0.370	-0.410	0.753
MAP3K8	mitogen-activated protein kinase kinase kinase 8	0.000301	0.207	-0.415	0.750
PPP3CC	protein phosphatase 3, catalytic subunit, gamma isozyme	0.00198953	0.370	-0.420	0.748
MPP3	membrane protein, palmitoylated 3 (MAGUK p55 subfamily member 3)	0.00097871	0.301	-0.423	0.746
TMTC1	transmembrane and tetratricopeptide repeat containing 1	0.0013494	0.338	-0.425	0.745
GPR4	G protein-coupled receptor 4	0.00404862	0.470	-0.428	0.743
IFNGR1	interferon gamma receptor 1	0.00012687	0.156	-0.429	0.743
SMAP2	small ArfGAP2	4.88E-05	0.137	-0.431	0.742
MT1B	metallothionein 1B	0.00278246	0.419	-0.433	0.741
VAMP8	vesicle-associated membrane protein 8 (endobrevin)	0.00111191	0.310	-0.436	0.739
IL17RA	interleukin 17 receptor A	0.0004218	0.223	-0.438	0.738
HCST	hematopoietic cell signal transducer	0.00032605	0.207	-0.443	0.736
IFITM4P	interferon induced transmembrane protein 4 pseudogene	0.00095487	0.301	-0.463	0.725
CALR	calreticulin	0.00276903	0.419	-0.465	0.724
IFITM4P	interferon induced transmembrane protein 4 pseudogene	0.00122516	0.325	-0.470	0.722
MT1DP	metallothionein 1D, pseudogene /// metallothionein 1D, pseudogene	0.00206797	0.370	-0.478	0.718

CEBPD	CCAAT/enhancer binding protein (C/EBP), delta	0.00214413	0.375	-0.479	0.717
STK17B	serine/threonine kinase 17b	0.00057997	0.247	-0.479	0.717
GNMT	glycine N-methyltransferase	0.0018093	0.360	-0.480	0.717
C1QB	complement component 1, q subcomponent, B chain	0.00159411	0.347	-0.492	0.711
TMEM45A	transmembrane protein 45A	0.00035573	0.213	-0.493	0.711
RNF144B	ring finger protein 144B	0.00285125	0.421	-0.500	0.707
IFITM3	interferon induced transmembrane protein 3	0.0039756	0.470	-0.509	0.703
S1PR3	sphingosine-1-phosphate receptor 3	0.0021775	0.377	-0.511	0.702
AIF1	allograft inflammatory factor 1	0.00087948	0.297	-0.514	0.700
FOXO3	forkhead box O3	0.00017806	0.179	-0.522	0.697
CPM	carboxypeptidase M	3.93E-05	0.124	-0.523	0.696
NFKBIA	nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha	0.00084533	0.294	-0.525	0.695
NFKBIZ	nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta	0.00251236	0.400	-0.538	0.689
IFITM4P	interferon induced transmembrane protein 4 pseudogene	0.0003967	0.220	-0.541	0.687
FOSL2	FOS-like antigen 2	0.0002609	0.194	-0.542	0.687
AASS	aminoadipate-semialdehyde synthase	0.00291745	0.425	-0.548	0.684
MTHFD2	methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase	0.00096372	0.301	-0.552	0.682
LRP1	low density lipoprotein receptor-related protein 1	0.00184927	0.364	-0.560	0.679
CD209	CD209 molecule	0.00122891	0.325	-0.563	0.677
LDHA	lactate dehydrogenase A	0.00030731	0.207	-0.571	0.673
IRAK3	interleukin-1 receptor-associated kinase 3	0.00074417	0.279	-0.574	0.672
BCAT1	branched chain amino-acid transaminase 1, cytosolic	0.00087519	0.297	-0.576	0.671
IFITM2	interferon induced transmembrane protein 2	0.0020637	0.370	-0.579	0.669
TGFBR2	transforming growth factor, beta receptor II (70/80kDa)	0.00106045	0.308	-0.587	0.666
TNFRSF1A	tumor necrosis factor receptor superfamily, member 1A	0.00153604	0.346	-0.587	0.666
SAT1	spermidine/spermine N1-acetyltransferase 1	0.0021567	0.376	-0.589	0.665
CCL18	chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated)	0.00197433	0.370	-0.592	0.663
SLCO4A1	solute carrier organic anion transporter family, member 4A1	0.00077152	0.286	-0.604	0.658
RGCC	regulator of cell cycle	0.00099195	0.302	-0.606	0.657
AREG	amphiregulin /// amphiregulin B	0.00382854	0.461	-0.608	0.656
LAMB1	laminin, beta 1	0.00167156	0.351	-0.608	0.656
PYGL	phosphorylase, glycogen, liver	0.00056939	0.246	-0.617	0.652
FCGR2A	Fc fragment of IgG, low affinity IIa, receptor (CD32)	0.00106489	0.308	-0.619	0.651
RHOU	ras homolog family member U	0.00061645	0.251	-0.622	0.650
ZBTB16	zinc finger and BTB domain containing 16	0.00182702	0.361	-0.624	0.649

IGFBP4	insulin-like growth factor binding protein 4	0.00223569	0.380	-0.625	0.649
SNAI2	snail homolog 2 (Drosophila)	0.00032442	0.207	-0.626	0.648
CPEB4	cytoplasmic polyadenylation element binding protein 4	8.89E-05	0.140	-0.633	0.645
DCLK1	doublecortin-like kinase 1	0.0033391	0.437	-0.633	0.645
MYC	v-myc myelocytomatosis viral oncogene homolog (avian)	0.00201717	0.370	-0.634	0.644
SLC9A9	solute carrier family 9, subfamily A (NHE9, cation proton antiporter 9), member 9	0.00121644	0.324	-0.644	0.640
SLC1A3	solute carrier family 1 (glial high affinity glutamate transporter), member 3	0.00023809	0.186	-0.645	0.640
PDGFRA	platelet-derived growth factor receptor, alpha polypeptide	0.0015716	0.347	-0.658	0.634
C1orf162	chromosome 1 open reading frame 162	0.00048959	0.230	-0.659	0.633
NCKAP1L	NCK-associated protein 1-like	0.00020059	0.179	-0.669	0.629
MERTK	c-mer proto-oncogene tyrosine kinase	0.00023205	0.186	-0.679	0.625
IL2RA	interleukin 2 receptor, alpha	0.00057691	0.247	-0.679	0.624
CLEC4E	C-type lectin domain family 4, member E	0.00042492	0.223	-0.680	0.624
STAT3	signal transducer and activator of transcription 3 (acute-phase response factor)	0.0005666	0.246	-0.683	0.623
MT1E	metallothionein-2-like /// metallothionein 1E	0.0004781	0.230	-0.684	0.622
LINC00341	long intergenic non-protein coding RNA 341	0.00029182	0.207	-0.687	0.621
SLC38A2	solute carrier family 38, member 2	0.00228489	0.383	-0.695	0.618
C5AR1	complement component 5a receptor 1	0.00045703	0.230	-0.700	0.616
FCGR2C	Fc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene)	0.0002092	0.179	-0.704	0.614
MT1H	metallothionein 1H	0.00101652	0.305	-0.712	0.611
HCLS1	hematopoietic cell-specific Lyn substrate 1	0.0004215	0.223	-0.714	0.610
CD53	CD53 molecule	0.00046111	0.230	-0.719	0.607
MAFB	v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian)	5.81E-05	0.137	-0.728	0.604
TSPYL2	TSPY-like 2	0.000188	0.179	-0.731	0.602
GPR183	G protein-coupled receptor 183	0.00146787	0.340	-0.737	0.600
LCP1	lymphocyte cytosolic protein 1 (L-plastin)	0.000312	0.207	-0.737	0.600
GPX3	glutathione peroxidase 3 (plasma)	0.00078525	0.287	-0.745	0.597
TUBA3C	tubulin, alpha 3c /// tubulin, alpha 3d	2.47E-05	0.102	-0.753	0.593
MAN1A1	mannosidase, alpha, class 1A, member 1	0.00348865	0.445	-0.759	0.591
BCL6	B-cell CLL/lymphoma 6	0.00029387	0.207	-0.764	0.589
NAMPT	nicotinamide phosphoribosyltransferase	0.00383478	0.461	-0.781	0.582
FCGR1B	Fc fragment of IgG, high affinity Ib, receptor (CD64) /// Fc fragment of IgG, high affinity Ic, receptor (CD64), pseudogene	0.00204752	0.370	-0.792	0.577
MS4A6A	membrane-spanning 4-domains, subfamily A, member 6A	0.00205473	0.370	-0.798	0.575
GPR34	G protein-coupled receptor 34	0.00158982	0.347	-0.798	0.575

C1R	complement component 1, r subcomponent /// complement component 1, r subcomponent	0.00016103	0.177	-0.809	0.571
C3AR1	complement component 3a receptor 1	0.00071684	0.273	-0.836	0.560
MGST1	microsomal glutathione S-transferase 1	8.88E-06	0.062	-0.838	0.559
LPCAT3	lysophosphatidylcholine acyltransferase 3	0.00034145	0.209	-0.840	0.559
ZNF189	zinc finger protein 189	8.21E-06	0.062	-0.849	0.555
FCGR1A	Fc fragment of IgG, high affinity Ia, receptor (CD64) /// Fc fragment of IgG, high affinity Ib, receptor (CD64)	0.00236892	0.388	-0.871	0.547
SAMHD1	SAM domain and HD domain 1	0.00114078	0.313	-0.890	0.539
GADD45B	growth arrest and DNA-damage-inducible, beta	0.00102324	0.305	-0.891	0.539
ALOX5AP	arachidonate 5-lipoxygenase-activating protein	9.32E-05	0.140	-0.899	0.536
MT1G	metallothionein 1G	0.00320585	0.433	-0.902	0.535
TLR2	toll-like receptor 2	8.91E-05	0.140	-0.934	0.523
C1QC	complement component 1, q subcomponent, C chain	0.00129441	0.335	-0.939	0.522
CCR1	chemokine (C-C motif) receptor 1	6.21E-05	0.140	-0.948	0.518
EFEMP1	EGF containing fibulin-like extracellular matrix protein 1	0.00056958	0.246	-0.956	0.516
FCGR3A	Fc fragment of IgG, low affinity IIIa, receptor (CD16a)	0.00034213	0.209	-0.964	0.513
IL1RL1	interleukin 1 receptor-like 1	0.00081458	0.292	-0.979	0.507
ERRFI1	ERBB receptor feedback inhibitor 1	7.32E-05	0.140	-0.986	0.505
MT2A	metallothionein 2A	0.0001734	0.179	-1.002	0.499
NNMT	nicotinamide N-methyltransferase	0.00098908	0.302	-1.015	0.495
FST	follistatin	0.00020189	0.179	-1.022	0.492
PLTP	phospholipid transfer protein	0.0004028	0.220	-1.052	0.482
EDNRB	endothelin receptor type B	0.00025294	0.192	-1.077	0.474
ADAMTS9	ADAM metalloproteinase with thrombospondin type 1 motif, 9	0.00221748	0.379	-1.079	0.473
MT1JP	metallothionein 1J, pseudogene	0.00045811	0.230	-1.102	0.466
GLUL	glutamate-ammonia ligase	7.27E-05	0.140	-1.104	0.465
OSMR	oncostatin M receptor	0.00023416	0.186	-1.109	0.464
CDH19	cadherin 19, type 2	0.00290402	0.425	-1.111	0.463
CD68	CD68 molecule	0.000193	0.179	-1.117	0.461
PLIN2	uncharacterized LOC100509484 /// perilipin 2	5.72E-05	0.137	-1.127	0.458
LAPTM5	lysosomal protein transmembrane 5	0.00074984	0.280	-1.145	0.452
CYBB	cytochrome b-245, beta polypeptide	0.00035589	0.213	-1.160	0.448
S100A8	S100 calcium binding protein A8	0.00010972	0.141	-1.163	0.447
MT1CP	metallothionein 1C, pseudogene	0.00016561	0.179	-1.187	0.439
FPR1	formyl peptide receptor 1	0.00125227	0.327	-1.207	0.433

MT1X	metallothionein 1X	0.00016819	0.179	-1.214	0.431
TUBA3C	tubulin, alpha 3c /// tubulin, alpha 3d	3.79E-06	0.053	-1.217	0.430
MS4A4A	membrane-spanning 4-domains, subfamily A, member 4A	0.00253196	0.400	-1.225	0.428
S100A12	S100 calcium binding protein A12	0.00232406	0.384	-1.260	0.418
BTG2	BTG family, member 2	8.22E-05	0.140	-1.264	0.416
C3	complement component 3	0.00102626	0.305	-1.331	0.397
CTSC	cathepsin C	0.00194506	0.370	-1.339	0.395
SRPX	sushi-repeat containing protein, X-linked	4.75E-06	0.056	-1.358	0.390
FCER1G	Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide	0.00047948	0.230	-1.362	0.389
ABRA	actin-binding Rho activating protein	0.0025267	0.400	-1.383	0.384
TUBA3E	tubulin, alpha 3e	6.61E-05	0.140	-1.394	0.381
MT1M	metallothionein 1M	4.04E-05	0.124	-1.470	0.361
RNASE2	ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin)	0.00020752	0.179	-1.486	0.357
ZFP36	zinc finger protein 36, C3H type, homolog (mouse)	0.00048998	0.230	-1.530	0.346
MRC1	mannose receptor, C type 1	0.00020262	0.179	-1.605	0.329
RASD1	RAS, dexamethasone-induced 1	2.77E-05	0.104	-1.673	0.314
VSIG4	V-set and immunoglobulin domain containing 4	0.0001281	0.156	-1.738	0.300
FKBP5	FK506 binding protein 5	3.90E-05	0.124	-1.770	0.293
S100A9	S100 calcium binding protein A9	1.89E-05	0.095	-1.800	0.287
F13A1	coagulation factor XIII, A1 polypeptide	5.59E-05	0.137	-1.812	0.285
LYVE1	lymphatic vessel endothelial hyaluronan receptor 1	4.51E-05	0.132	-1.929	0.263
PLA2G2A	phospholipase A2, group IIA (platelets, synovial fluid)	1.84E-07	0.006	-2.035	0.244
SERPINA3	serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3	9.75E-06	0.062	-2.184	0.220
CD163	CD163 molecule	2.43E-06	0.043	-2.374	0.193
MT1A	metallothionein 1A	1.52E-05	0.083	-2.882	0.136